Given the small numbers of patients, we had too little power to confirm or refute ER status findings from Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer.24 Similarly, the number of patients with leptomeningeal disease was too small to draw firm conclusions. This evidence concerns the gene ESR1 and breast cancer.